Korea's Celltrion and Sanofi-Aventis In Line With 2008 Strategic Alliance For Monoclonal Antibodies
This article was originally published in PharmAsia News
Executive Summary
SEOUL - Despite Celltrion's claims that it is shifting away from its contract manufacturing business to focus on biosimilars, the company revealed an ongoing deal with Sanofi-Aventis for clinical materials and process development for monoclonal antibody therapeutics and announced the near completion of its CMO plant
You may also be interested in...
Optimism Building For Korea's Celltrion Amid Expectations For Biosimilars
SEOUL - Optimism is building for South Korea's biopharmaceutical firm Celltrion and its biosimilar program, as seen in the recent surge of its stock price
Optimism Building For Korea's Celltrion Amid Expectations For Biosimilars
SEOUL - Optimism is building for South Korea's biopharmaceutical firm Celltrion and its biosimilar program, as seen in the recent surge of its stock price
Korea's Celltrion Completes Phase I Clinical Trials For Biosimilars Based On Roche And Johnson & Johnson Products
SEOUL - South Korean biotech firm Celltrion said it has successfully completed Phase I clinical trials on its biosimilar versions of Roche's oncology agent Herceptin (trastuzumab) and Johnson & Johnson's rheumatoid arthritis agent Remicade(infliximab)